Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Chronic Spontaneous Urticaria · Asthma

Novartis India

Novartis Pharmaceuticals

Novartis India clinical programs — 341 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mumbai, IN
Founded
1996
Employees
2,240
Programs
341
Drugs
317
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Novartis India projects

341 ClinicalTrials.gov programs sponsored by Novartis India.

Novartis India has 341 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

341 programs

Clinical programs

Page 5 of 8

  1. CLXH254C12201

    Novartis Pharmaceuticals

    Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

    phase 2 small molecule active

    1 trial

  2. CMAS825D12201

    Novartis Pharmaceuticals

    Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.

    phase 2 small molecule active

    1 trial

  3. CMBG453B12206B

    Novartis Pharmaceuticals

    intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy

    phase 2 small molecule active

    1 trial

  4. CPHE885B12201

    Novartis Pharmaceuticals

    Adult patients with relapsed and refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  5. CPK850

    Novartis Pharmaceuticals

    Retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene

    phase 2 small molecule active

    1 trial

  6. CPKC412A2218

    Novartis Pharmaceuticals

    untreated FLT3-mutated Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  7. CPKN605A12201

    Novartis Pharmaceuticals

    Atrial Fibrillation

    phase 2 small molecule active

    1 trial

  8. CQUC398A12201

    Novartis Pharmaceuticals

    Knee osteoarthritis

    phase 2 small molecule active

    1 trial

  9. CQVM149C2201

    Novartis Pharmaceuticals

    Asthma

    phase 2 small molecule active

    1 trial

  10. CSJ117

    Novartis Pharmaceuticals

    Asthma

    phase 2 small molecule terminated

    2 trials

  11. CTIN816A12201

    Novartis Pharmaceuticals

    Acute kidney injury

    phase 2 small molecule active

    1 trial

  12. CTIN816B12202

    Novartis Pharmaceuticals

    Sepsis associated acute kidney injury

    phase 2 small molecule active

    1 trial

  13. CTQJ230A12203

    Novartis Pharmaceuticals

    Calcific Aortic Valve Stenosis

    phase 2 small molecule active

    1 trial

  14. CVAY736A2103

    Novartis Pharmaceuticals

    Sjögren's syndrome

    phase 2 small molecule active

    1 trial

  15. CVAY736A2202

    Novartis Pharmaceuticals

    Rheumatoid Arthritis, Sjögren’s Disease, Systemic Lupus erythematosus

    phase 2 small molecule active

    1 trial

  16. CVAY736Q12202B

    Novartis Pharmaceuticals

    Immune thrombocytopenia (ITP) Warm autoimmune hemolytic anemia (wAIHA)

    phase 2 small molecule active

    1 trial

  17. CVAY736S12201

    Novartis Pharmaceuticals

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial

  18. CVHB937A12201

    Novartis Pharmaceuticals

    Alzheimer’s disease

    phase 2 small molecule active

    1 trial

  19. CVHB937B12201

    Novartis Pharmaceuticals

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  20. CXXB750A12201

    Novartis Pharmaceuticals

    Heart Failure

    phase 2 small molecule active

    1 trial

  21. CYTB323A12101

    Novartis Pharmaceuticals

    High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  22. CYTB323G12101

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus., Lupus Nephritis

    phase 2 small molecule active

    1 trial

  23. CYTB323J12201

    Novartis Pharmaceuticals

    Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)

    phase 2 small molecule active

    1 trial

  24. CYTB323K12201

    Novartis Pharmaceuticals

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial

  25. CYTB323L12201

    Novartis Pharmaceuticals

    Severe refractory idiopathic inflammatory myopathies (IIM)

    phase 2 small molecule active

    1 trial

  26. CYTB323M12101B

    Novartis Pharmaceuticals

    Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement

    phase 2 small molecule active

    1 trial

  27. CYTB323N12101

    Novartis Pharmaceuticals

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  28. CYTB323O12101

    Novartis Pharmaceuticals

    Treatment-resistant generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  29. CYTB323R12101

    Novartis Pharmaceuticals

    Non-active Progressive Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  30. Canakinumab 150 mg

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  31. Capecitabine

    Novartis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  32. Ceritinib (LDK378)

    Novartis Pharmaceuticals

    Tumors With Aberrations in ALK

    phase 2 small molecule terminated

    1 trial

  33. DYP688

    Novartis Pharmaceuticals

    Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)

    phase 2 small molecule active

    1 trial

  34. Dabrafenib

    Novartis Pharmaceuticals

    Cancer

    phase 2 small molecule completed

    1 trial

  35. Deferasirox

    Novartis Pharmaceuticals

    Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  36. Deferasirox granule formulation

    Novartis Pharmaceuticals

    Transfusion-dependent Anemia

    phase 2 small molecule completed

    1 trial

  37. EYU688

    Novartis Pharmaceuticals

    Dengue

    phase 2 small molecule active

    1 trial

  38. Eltrombopag

    Novartis Pharmaceuticals

    Aplastic Anemia

    phase 2 small molecule completed

    1 trial

  39. FGF401

    Novartis Pharmaceuticals

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule completed

    1 trial

  40. GIA632

    Novartis Pharmaceuticals

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  41. HCD122

    Novartis Pharmaceuticals

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  42. INC280

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  43. Iptacopan

    Novartis Pharmaceuticals

    Immune Thrombocytopenia (ITP)

    phase 2 small molecule terminated

    1 trial

  44. JDQ443

    Novartis Pharmaceuticals

    Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

    phase 2 small molecule active

    1 trial

  45. KAE609

    Novartis Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  46. KAE609

    Novartis Pharmaceuticals

    Cure Rate

    phase 2 small molecule completed

    1 trial

  47. KAF156

    Novartis Pharmaceuticals

    Acute Uncomplicated Plasmodium Falciparum Malaria

    phase 2 small molecule completed

    1 trial

  48. KAF156

    Novartis Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Novartis India have?

341 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.